Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $(0.13) by 576.92 percent. This is a 100 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $467.172 million which beat the analyst consensus estimate of $409.297 million by 14.14 percent. This is a 40.79 percent increase over sales of $331.817 million the same period last year.
Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated